Total Payments
$452,427
2024 Payments
$51,714
Companies
17
Transactions
545
Medicare Patients
471
Medicare Billing
$53,015
Payment Breakdown by Category
Other$303,771 (67.1%)
Consulting$77,991 (17.2%)
Travel$60,485 (13.4%)
Food & Beverage$10,180 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $299,051 | 116 | 66.1% |
| Consulting Fee | $77,991 | 49 | 17.2% |
| Travel and Lodging | $60,485 | 251 | 13.4% |
| Food and Beverage | $10,180 | 128 | 2.3% |
| Honoraria | $4,720 | 1 | 1.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $214,778 | 337 | $0 (2023) |
| GlaxoSmithKline, LLC. | $157,057 | 131 | $0 (2024) |
| PFIZER INC. | $13,866 | 12 | $0 (2024) |
| Henry Schein, Inc. | $12,300 | 11 | $0 (2022) |
| Shionogi Inc | $11,759 | 14 | $0 (2024) |
| SANOFI PASTEUR INC. | $10,466 | 5 | $0 (2023) |
| Emergent BioSolutions Inc. | $8,000 | 3 | $0 (2021) |
| Becton, Dickinson and Company | $6,055 | 10 | $0 (2024) |
| Seqirus USA Inc | $6,029 | 4 | $0 (2024) |
| Roche Diagnostics Corporation | $4,593 | 7 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $51,714 | 53 | GlaxoSmithKline, LLC. ($45,176) |
| 2023 | $140,607 | 130 | GlaxoSmithKline, LLC. ($102,132) |
| 2022 | $36,550 | 27 | GlaxoSmithKline, LLC. ($9,750) |
| 2021 | $11,709 | 10 | Merck Sharp & Dohme Corporation ($5,475) |
| 2020 | $36,316 | 37 | Merck Sharp & Dohme Corporation ($19,554) |
| 2019 | $65,857 | 110 | Merck Sharp & Dohme Corporation ($65,857) |
| 2018 | $64,953 | 106 | Merck Sharp & Dohme Corporation ($64,953) |
| 2017 | $44,720 | 72 | Merck Sharp & Dohme Corporation ($40,000) |
All Payment Transactions
545 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | Becton, Dickinson and Company | — | Consulting Fee | Cash or cash equivalent | $612.50 | General |
| 12/05/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $120.13 | General |
| Category: Infections and Infectious Diseases | ||||||
| 12/04/2024 | Melinta Therapeutics, LLC | Rezzayo (Drug) | Food and Beverage | In-kind items and services | $104.78 | General |
| Category: ANTIFUNGALS | ||||||
| 11/21/2024 | PFIZER INC. | PAXLOVID (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 11/04/2024 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $5.76 | General |
| 10/18/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $222.65 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 10/17/2024 | Seqirus USA Inc | — | Food and Beverage | In-kind items and services | $31.51 | General |
| 10/14/2024 | Melinta Therapeutics, LLC | — | Food and Beverage | In-kind items and services | $46.18 | General |
| 09/06/2024 | Becton, Dickinson and Company | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 09/06/2024 | Becton, Dickinson and Company | — | Consulting Fee | Cash or cash equivalent | $575.00 | General |
| 06/20/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $910.00 | General |
| 03/28/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,925.00 | General |
| Category: RESPIRATORY | ||||||
| 03/15/2024 | Shionogi Inc | — | Consulting Fee | Cash or cash equivalent | $348.75 | General |
| 03/06/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,300.00 | General |
| Category: RESPIRATORY | ||||||
| 02/28/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 02/26/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 02/22/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 02/22/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: RESPIRATORY | ||||||
| 02/22/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $286.94 | General |
| Category: RESPIRATORY | ||||||
| 02/22/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $262.04 | General |
| Category: RESPIRATORY | ||||||
| 02/22/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $4.49 | General |
| Category: RESPIRATORY | ||||||
| 02/22/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | Cash or cash equivalent | $3.61 | General |
| Category: RESPIRATORY | ||||||
| 02/22/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Travel and Lodging | Cash or cash equivalent | $2.02 | General |
| Category: RESPIRATORY | ||||||
| 02/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
| 02/14/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 88 | 208 | $25,540 | $13,941 |
| 2022 | 3 | 113 | 166 | $22,236 | $11,141 |
| 2021 | 3 | 137 | 199 | $27,195 | $14,473 |
| 2020 | 3 | 133 | 190 | $25,159 | $13,461 |
Total Patients
471
Total Services
763
Medicare Billing
$53,015
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 71 | 189 | $20,790 | $11,410 | 54.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 19 | $4,750 | $2,531 | 53.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 82 | 134 | $14,776 | $7,246 | 49.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 14 | $3,500 | $2,014 | 57.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 18 | 18 | $3,960 | $1,881 | 47.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 98 | 158 | $17,380 | $8,897 | 51.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 26 | $6,515 | $3,981 | 61.1% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 15 | $3,300 | $1,596 | 48.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 100 | 157 | $17,276 | $8,972 | 51.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 22 | 22 | $5,573 | $3,297 | 59.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 11 | 11 | $2,310 | $1,191 | 51.6% |
About Dr. Amesh Adalja, MD
Dr. Amesh Adalja, MD is a Emergency Medicine healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1023209871.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Amesh Adalja, MD has received a total of $452,427 in payments from pharmaceutical and medical device companies, with $51,714 received in 2024. These payments were reported across 545 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($299,051).
As a Medicare-enrolled provider, Adalja has provided services to 471 Medicare beneficiaries, totaling 763 services with total Medicare billing of $53,015. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Emergency Medicine
- Other Specialties Emergency Medical Services, Critical Care Medicine
- Location Pittsburgh, PA
- Active Since 08/07/2007
- Last Updated 07/06/2022
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1023209871
Products in Payments
- ZERBAXA (Drug) $174,504
- AREXVY (Drug) $140,467
- PAXLOVID (Drug) $11,116
- Fetroja (Drug) $8,961
- SIVEXTRO (Drug) $8,000
- RECARBRIO (Drug) $5,665
- DIFICID (Drug) $5,482
- CD cobas Reagents (Device) $3,218
- PREVNAR 20 (Biological) $2,750
- SHINGRIX (Biological) $1,950
- POC cobas Liat Analyzer, Assays, Controls and Accessories (Device) $1,375
- Kimyrsa (Drug) $710.95
- PREVYMIS (Drug) $114.67
- Vabomere (Drug) $105.47
- Rezzayo (Drug) $104.78
- Cresemba (Drug) $100.00
- ACCELERATE PHENO (Device) $26.67
- TRELEGY ELLIPTA (Drug) $4.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in Pittsburgh
Dr. Alan Shapiro, D.o, D.O
Emergency Medicine — Payments: $86,215
Emergency Medicine $86,215
Arvind Venkat, Md, MD
Emergency Medicine — Payments: $73,114
Emergency Medicine $73,114
Dr. David Chuirazzi, Md, MD
Emergency Medicine — Payments: $22,090
Emergency Medicine $22,090
Breanna Kebort, M.d, M.D
Emergency Medicine — Payments: $10,180
Emergency Medicine $10,180
Dr. John O'neill, Md, MD
Emergency Medicine — Payments: $5,785
Emergency Medicine $5,785
Dr. Jeremy Gilbert, D.o.,, D.O.,
Emergency Medicine — Payments: $5,606
Emergency Medicine $5,606